Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis
Version of Record online: 30 APR 2009
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 15, Issue 11, pages 1678–1685, November 2009
How to Cite
Storr, M. A., Keenan, C. M., Zhang, H., Patel, K. D., Makriyannis, A. and Sharkey, K. A. (2009), Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis, 15: 1678–1685. doi: 10.1002/ibd.20960
- Issue online: 14 OCT 2009
- Version of Record online: 30 APR 2009
- Manuscript Accepted: 17 MAR 2009
- Manuscript Received: 10 MAR 2009
- Crohn's and Colitis Foundation of Canada
- Canadian Institutes of Health Research
- Keith Sharkey is an AHFMR Medical Scientist and holds the Crohn's and Colitis Foundation of Canada Chair in IBD Research at University of Calgary
- Kamala Patel is an AHFMR Senior Scholar and Canada Research Chair
- cannabinoid 2 receptor;
- inflammatory bowel disease
Activation of cannabinoid (CB)1 receptors results in attenuation of experimental colitis. Our aim was to examine the role of CB2 receptors in experimental colitis using agonists (JWH133, AM1241) and an antagonist (AM630) in trinitrobenzene sulfonic acid (TNBS)-induced colitis in wildtype and CB2 receptor-deficient (CB mice.
Mice were treated with TNBS to induce colitis and then given intraperitoneal injections of the CB2 receptor agonists JWH133, AM1241, or the CB2 receptor antagonist AM630. Additionally, CB mice were treated with TNBS and injected with JWH133 or AM1241. Animals were examined 3 days after the induction of colitis. The colons were removed for macroscopic and microscopic evaluation, as well as the determination of myeloperoxidase activity. Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) for CB2 receptor was also performed in animals with TNBS and dextran sodium sulfate colitis.
Intracolonic installation of TNBS caused severe colitis. CB2 mRNA expression was significantly increased during the course of experimental colitis. Three-day treatment with JWH133 or AM1241 significantly reduced colitis; AM630 exacerbated colitis. The effect of JWH133 was abolished when animals were pretreated with AM630. Neither JWH133 nor AM1241 had effects in CB mice.
We show that activation of the CB2 receptor protects against experimental colitis in mice. Increased expression of CB2 receptor mRNA and aggravation of colitis by AM630 suggests a role for this receptor in normally limiting the development of colitis. These results support the idea that the CB2 receptor may be a possible novel therapeutic target in inflammatory bowel disease. (Inflamm Bowel Dis 2009)